Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Takeda licenses Potelligent technology for antibody R&D
June 2007
SHARING OPTIONS:

OSAKA, Japan—BioWa Inc. and Takeda Pharmaceutical Co. Ltd. announced in May that the companies have entered into an agreement which provides Takeda with access to BioWa's patented Potelligent Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.
 
The agreement grants Takeda non-exclusive rights to research, develop, manufacture and commercialize antibodies based on Potelligent Technology for an undisclosed number of targets. In return, BioWa will receive an upfront fee, license fees, development milestone payments and also royalties on products developed by Takeda once they are successfully marketed. Other details of the agreement were not disclosed.
 
"With Takeda's expertise in drug development and commercialization, this collaboration reinforces BioWa's mission to bring the benefit of Potelligent Technology to patients as quickly as possible," says Dr. Masamichi Koike, president and CEO of BioWa.
 
"We believe that the collaboration with BioWa Inc. will accelerate our drug discovery and development activities in therapeutic antibodies, a field that is expected to be potential as an important source of new medicines to satisfy unmet medical needs," says Shigenori Ohkawa, Ph.D., GM of  the pharmaceutical research division of Takeda.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.